IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
31.23
-0.03 (-0.10%)
Jun 18, 2026, 4:00 PM EDT - Market closed
IDEAYA Biosciences Revenue
IDEAYA Biosciences had revenue of $6.56M in the quarter ending March 31, 2026. This brings the company's revenue in the last twelve months to $225.27M, up 3,118.14% year-over-year. In the year 2025, IDEAYA Biosciences had annual revenue of $218.71M with 3,024.43% growth.
Revenue (ttm)
$225.27M
Revenue Growth
+3,118.14%
P/S Ratio
12.18
Revenue / Employee
$1,553,586
Employees
145
Market Cap
2.74B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 218.71M | 211.71M | 3,024.43% |
| Dec 31, 2024 | 7.00M | -16.39M | -70.07% |
| Dec 31, 2023 | 23.39M | -27.55M | -54.08% |
| Dec 31, 2022 | 50.93M | 22.99M | 82.28% |
| Dec 31, 2021 | 27.94M | 8.40M | 43.01% |
| Dec 31, 2020 | 19.54M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ultragenyx Pharmaceutical | 670.00M |
| Tarsus Pharmaceuticals | 535.08M |
| Arcus Biosciences | 236.00M |
| uniQure | 18.09M |
| Alumis | 8.40M |
| Celldex Therapeutics | 865.00K |
IDYA News
- 4 days ago - Ideaya Biosciences elects CEO Yujiro Hata as chairman - TheFly
- 4 days ago - IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors - PRNewsWire
- 6 days ago - Ideaya Biosciences enrolls first patient in IDE892 trial - TheFly
- 6 days ago - IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers - PRNewsWire
- 11 days ago - IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - PRNewsWire
- 12 days ago - Ideaya Biosciences 5.56M share Spot Secondary priced at $27.00 - TheFly
- 13 days ago - IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants - PRNewsWire
- 13 days ago - Ideaya Biosciences $300M Spot Secondary re-offered at $27.00 - TheFly